Medline shares surge 30.55% intraday after $6.26B IPO values company at $50B.

Medline surged 30.55% intraday after completing the year's largest IPO, raising $6.26 billion by selling 216 million shares at $29 each, valuing the medical supply giant at $39 billion. The public offering, upsized due to strong institutional demand, enabled debt reduction and provided liquidity to pre-IPO owners. The stock’s sharp rise followed its Nasdaq debut on December 17, 2025, with shares opening 6.9% above the IPO price. The listing, led by private equity-backed Blackstone, Carlyle, and Hellman & Friedman, marked a pivotal moment for the healthcare supply-chain leader, which operates 69 facilities and delivers to 95% of U.S. customers. Analysts highlighted the IPO’s role in signaling a potential revival of 2026’s IPO market, with Medline’s operational scale, consistent profitability, and deleveraging strategy attracting investor confidence. The debut also underscored the sector’s resilience amid broader market volatility and tariff risks.